Clinical Trials

GastrointestinalGynecologicThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03939481 2026-04-13

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

Active not recruiting

1,336 enrolled

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms

NCT01445275 2024-08-21

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Withdrawn

BreastGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

NCT01941316 2024-05-09

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Phase 1/2 Completed

78 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT01402271 2023-12-11

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1/2 Completed

88 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03412630 2023-11-24

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Phase NA Terminated

1 enrolled 1 chart

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

131 enrolled 18 charts 1 FDA

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

NCT00993655 2023-08-28

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

BreastGenitourinaryGynecologicThoracic

275 enrolled 13 charts

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pleural Effusion, Malignant

NCT00471432 2023-08-04

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Phase 1 Completed

40 enrolled

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male

NCT00003308 2023-06-22

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

CNSDermatologicGenitourinaryGynecologicSarcoma

Brain Neoplasms, Carcinoma, Renal Cell, Chondrosarcoma, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT00003518 2023-06-22

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

44 enrolled

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Testicular Neoplasms

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

122 enrolled

Ovarian Neoplasms

NCT00886691 2022-02-04

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

150 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00888615 2021-10-20

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

58 enrolled 13 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01720173 2021-10-20

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

30 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00954174 2021-09-30

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 3 Unknown

637 enrolled 18 charts

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01139957 2020-09-02

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Completed

1,916 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01535157 2020-08-27

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Phase 1/2 Terminated

12 enrolled

Ovarian Neoplasms

NCT00030446 2020-04-08

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

50 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003892 2020-04-06

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

22 enrolled

CNSGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00006036 2020-04-06

Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Completed

14 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

NCT00010179 2020-04-06

Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

81 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00028743 2020-04-02

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

819 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00305695 2020-03-24

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

160 enrolled 10 charts

BreastGynecologic

Osteoporosis, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

NCT00693342 2020-02-24

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Phase 3 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00445887 2019-11-19

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

60 enrolled 9 charts

Ovarian Neoplasms

NCT00003644 2019-06-04

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

571 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Brenner Tumor, Ovarian Neoplasms

NCT00011986 2019-04-16

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

4,312 enrolled 14 charts

Ovarian Neoplasms

NCT00407758 2019-03-20

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

28 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00958698 2019-03-12

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase NA Unknown

485 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01372787 2019-03-12

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Unknown

103 enrolled

Anxiety Disorders, Fallopian Tube Neoplasms, Fatigue, Nausea, Ovarian Neoplasms, Vomiting, Neurotoxicity Syndromes

NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 1 Completed

16 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00939809 2019-01-15

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

31 enrolled 9 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00114166 2018-07-24

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

81 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00459290 2018-07-18

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

24 enrolled 12 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00569673 2018-07-18

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

71 enrolled 8 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00899093 2018-05-22

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Terminated

2,500 enrolled

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01275664 2018-05-22

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Phase NA Terminated

4 enrolled 5 charts

Brenner Tumor, Fallopian Tube Neoplasms, Nausea, Ovarian Neoplasms, Vomiting

NCT01295489 2018-05-22

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed

39 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005029 2018-04-12

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01080521 2018-04-12

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Completed

247 enrolled

Teratoma, Ovarian, Brenner Tumor, Dysgerminoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00499252 2018-01-11

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

51 enrolled 8 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00574951 2018-01-11

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Terminated

23 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01118052 2018-01-11

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

22 enrolled 8 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00857545 2017-09-13

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

171 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01039207 2017-09-07

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

31 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00004221 2017-08-09

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Phase 2 Terminated

12 enrolled

Ovarian Neoplasms

NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Phase NA Withdrawn